When Cell and Gene Therapies Surge to Market, How Resilient Will Your Cell Sourcing Infrastructure Be?
Nullam velit nulla commodo sem, at egestas nulla metus vel imperdiet aptent taciti ad litora torquent per.
From Clinic to Commercial Reality: Leveraging Transplant Experience to Overcome Cell Therapy Supply Chain Hurdles
View this on-demand presentation of From Clinic to Commercial Reality by our Director of Cell and Gene Therapy Operations, Jamie Margolis, PhD, and our Vice President of Business Development and Strategic Partnerships, Mark Flower, to learn more about how NMDP BioTherapies (formerly Be The Match BioTherapies) is going beyond hematopoietic cell transplant and leveraging 30+…
Strategies to Relieve the Burden on Apheresis & Collection Centers
As cell and gene therapies continue to progress at a rapid pace, apheresis and collection centers face the challenges of keeping up with demand, while maintaining high-quality levels. View this on-demand webinar for an in-depth discussion of standardization strategies that can bring efficiencies to the apheresis and collection infrastructure. Also included is a Q&A session…
Critical Components for Developing & Managing Expansive, High-Performing Collection Networks
A high-performing collection center network is essential to providing and delivering quality starting material for emerging cell and gene therapies. Learn about effective practices for building and maintaining collection networks in our on-demand webinar, Critical Components for Developing & Managing Expansive, High-Performing Collection Networks. Amy Hines, BSN, RN, director, Collection Network Management, Be The Match BioTherapies®,…
How Starting Material Quality Impacts the Manufacturing and Success of Next-Generation Therapies
This on-demand webinar helps answer the question, “What constitutes quality allogeneic cell therapy starting material and how you can ensure it?” The webinar explores specific risks and practical downstream repercussions of insufficient and variable starting material quality. Our expert panelists discuss how to help ensure both high-quality and consistent cellular starting material by building efficiencies…
Scaling Up and Out: Developing a Commercial Supply Chain Strategy to Successfully Deliver Next-Generation Therapies
With the introduction of innovative cell and gene therapies to market, scalable commercial supply chain strategies are critical to successfully delivering these therapies to patients. The delivery of cell and gene therapies depends on well-designed supply chains. Scaling your supply chain up to achieve this requires having, or finding partners with, proven experience in navigating…
Focusing on Donor Characteristics and Efficient Selection to Improve Allogeneic Cell Therapy Outcomes
View this on-demand webinar for an in-depth discussion of efficiencies in donor selection to reduce uncertainties about HLA matching and improve patient outcomes. A 20-min presentation by Martin Maiers, MS, Vice President of Biomedical Informatics, CIBMTR® (Center for International Blood and Marrow Transplant Research®) is followed by a 40-min Q&A session featuring the following well-known…
Size Matters: Ensuring Donor Pool Sustainability and Cell Therapy Supply Chain Success When Scaling Up and Out
View this on-demand webinar to learn how to increase potential for long-term success and ensure donor pool sustainability in allogeneic and autologous programs. Discover the keys to enabling a smoother, faster transition to market and ultimately, access to more patients. Our expert panelists will cover: What to expect when transitioning from small trial sizes to…
Streamlining Your Supply Chain to Support Next-Gen Therapies
As your cell and gene therapies move from early-phase clinical trials to commercialization, your supply chain complexity—and risk—increases. Anticipating setbacks and planning for their solution requires a specialized and collaborative approach with your supply chain partner. During this on-demand webinar, you’ll hear from industry experts who offer insights into developing a commercial supply chain for emerging autologous and allogeneic…